The renal toxicity ADME toxicology testing market is projected to reach $2.78B by 2030 at 12.9% CAGR, driven by AI safety analytics, organ-on-chip platforms, predictive models, and high-throughput renal assays.
Read More
The regenerative therapies for osteoarthritis market is projected to reach $5.88B by 2030 at 14.2% CAGR, driven by stem cell, PRP, scaffold-based cartilage repair, and personalized biologics.
Read More
The regenerative artificial skin market is projected to reach $3.84B by 2030 at 12.3% CAGR, driven by cell-based therapies, advanced wound care, and personalized skin graft innovations.
Read More
The refurbished cardiovascular and cardiology equipment market is projected to reach $7.43B by 2030 at 9.9% CAGR, driven by cost-optimized care, certified refurbished adoption, and expanding cardiac diagnostics access.
Read More
The recurrent pericarditis market is projected to reach $1.32B by 2030 at 10.8% CAGR, driven by biologic adoption, targeted cytokine inhibitors, specialty cardiology expansion, and structured recurrence prevention.
Read More
The recombinant vaccines market is projected to reach $28.07B by 2030 at 12.2% CAGR, driven by precision vaccines, emerging disease programs, adult boosters, and advanced recombinant platforms.
Read More
The recombinant proteins manufacturing services market is projected to reach $7.12B by 2030 at 14% CAGR, driven by protein therapeutics pipelines, pharma outsourcing, and GMP bioprocessing demand.
Read More
The recombinant human GCSF injection market is projected to reach $5.86B by 2030 at 8.6% CAGR, driven by cancer care demand, biosimilar adoption, and long-acting injectables.
Read More
The quantitative brain function imaging device market is projected to reach $9.3B by 2030 at an 8.9% CAGR, driven by multimodal imaging, functional brain mapping, advanced neuro software, psychiatric diagnostics, and portable monitoring systems.
Read More
The pyoderma gangrenosum treatment market is projected to reach $2.12B by 2030 at a 12.1% CAGR, driven by biologic therapies, combination drug regimens, advanced wound care, personalized treatments, and expanded clinical monitoring.
Read More